Pevonedistat hydrochloride is under clinical development by Millennium Pharmaceuticals and currently in the Phase I, Phase II and Phase III in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.
According to GlobalData, the latest event to affect Pevonedistat hydrochloride’s likelihood of approval (LoA) and phase transition for Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) took place on 15 Sep 2022, which decreased the likelihood that the drug progresses to the next phase in its clinical pathway and decreased the likelihood of final approval for this indication.
GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Pevonedistat hydrochloride Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.
Pevonedistat hydrochloride overview
Pevonedistat (MLN4924) is under development for the treatment of myelodysplastic syndrome, recurrent ovarian cancer, hematologic malignancies such as acute myelocytic leukemia, high risk myelodysplastic syndrome, relapsed/refractory multiple myeloma, myelofibrosis and chronic myelomonocytic leukemia, acute lymphocytic leukemia, essential thrombocythemia, post-polycythemia vera myelofibrosis (PPV-MF). It is administered through intravenous route. It is a small molecule which acts by targeting NEDD8 Activating Enzyme (Nae) with potent anti-tumor activity. It was also under development for diffuse large B-cell lymphoma, Waldenstrom's macroglobulinemia, Hodgkin lymphoma, mantle cell lymphoma, metastatic melanoma and solid tumors including ovarian cancer, hepatocellular carcinoma, lung cancer, colon cancer, relapsed and refractory acute lymphocytic leukemia.
Millennium Pharmaceuticals overview
Millennium Pharmaceuticals is a biopharmaceutical company that offers cancer therapy for the treatment of patients with multiple myeloma and relapsed mantle cell lymphoma. It is headquartered in Cambridge, Massachusetts, the US.
Quick View Pevonedistat hydrochloride LOA Data
|Highest Development Stage|